Delcath Systems (DCTH) announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems publishes review of Hepzato Kit
- Delcath announces publication supporting early use of liver-directed therapy
- Delcath Systems’ Earnings Call: Mixed Sentiments and Future Plans
- Delcath Systems Reports Strong Q3 2025 Growth
- DCTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?